Cargando…

Combining machine learning algorithms for prediction of antidepressant treatment response

OBJECTIVES: Predictors for unfavorable treatment outcome in major depressive disorder (MDD) applicable for treatment selection are still lacking. The database of a longitudinal multicenter study on 1079 acutely depressed patients, performed by the German research network on depression (GRND), allows...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kautzky, Alexander, Möller, Hans‐Juergen, Dold, Markus, Bartova, Lucie, Seemüller, Florian, Laux, Gerd, Riedel, Michael, Gaebel, Wolfgang, Kasper, Siegfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839691/ https://www.ncbi.nlm.nih.gov/pubmed/33141944 http://dx.doi.org/10.1111/acps.13250

Ejemplares similares

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited
por: Bartova, Lucie, et al.
Publicado: (2022)

A factor analytic comparison of three commonly used depression scales (HAMD, MADRS, BDI) in a large sample of depressed inpatients
por: Seemüller, Florian, et al.
Publicado: (2023)

Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials
por: Dold, Markus, et al.
Publicado: (2023)

The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
por: Fugger, Gernot, et al.
Publicado: (2022)

Silexan for treatment of anxiety and depression in the context of COVID-19
por: Bartova, Lucie, et al.
Publicado: (2023)

PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)

Age as a moderating factor of treatment resistance in depression
por: Kautzky, Alexander, et al.
Publicado: (2023)

Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients
por: Seemüller, Florian, et al.
Publicado: (2016)

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)
por: Dold, Markus, et al.
Publicado: (2018)

The media and intellectuals' response to medical publications: the antidepressants' case
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2013)

Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression
por: Bartova, Lucie, et al.
Publicado: (2021)

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
por: Dold, M., et al.
Publicado: (2018)

How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial
por: Adli, Mazda, et al.
Publicado: (2017)

Milnacipran: a unique antidepressant?
por: Kasper, Siegfried, et al.
Publicado: (2010)

Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression
por: Fugger, Gernot, et al.
Publicado: (2020)

Is the PANSS used correctly? a systematic review
por: Obermeier, Michael, et al.
Publicado: (2011)

Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders
por: Jäger, Markus, et al.
Publicado: (2006)

Initiating Antidepressant Medication: What is the Most Important Factor?
por: Kasper, Siegfried
Publicado: (2022)

Prediction of Autopsy Verified Neuropathological Change of Alzheimer’s Disease Using Machine Learning and MRI
por: Kautzky, Alexander, et al.
Publicado: (2018)

Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication?
por: Seemüller, Florian, et al.
Publicado: (2012)

Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
por: Dold, Markus, et al.
Publicado: (2015)

Silexan for treatment of psychiatric manifestations in the context of COVID-19: a case series
por: Bartova, L., et al.
Publicado: (2023)

PM478. Imaging the effects of d-amphetamine in the human brain for modelling dopaminergic alterations in schizophrenia
por: Willeit, Matthäus, et al.
Publicado: (2016)

Case Report: Bupropion Reduces the [(123)I]FP-CIT Binding to Striatal Dopamine Transporter
por: Milenkovic, Ivan, et al.
Publicado: (2021)

The Toxicity Potential of Antidepressants and Antipsychotics in Relation to Other Medication and Alcohol: A Naturalistic and Retrospective Study
por: Swoboda, Marleen M. M., et al.
Publicado: (2022)

Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study
por: Kautzky, A., et al.
Publicado: (2018)

Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression
por: Severus, Emanuel, et al.
Publicado: (2012)

The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants
por: Baumann, Pierre, et al.
Publicado: (2005)

PS87. An update on prediction of treatment outcome in treatment resistant depression
por: Kautzky, Alexander, et al.
Publicado: (2016)

ICD-11 and mental disorders: important changes, controversies, and future directions
por: Seemüller, Florian
Publicado: (2023)

PM476. d-Amphetamine-induced sensitization of the dopaminergic system in healthy human subjects: A [(11)C]-(+)-PHNO-PET study
por: Ana, Popovic, et al.
Publicado: (2016)

Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Combining antidepressants
por: DUNNER, David L
Publicado: (2014)

Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder?
por: Berger, Michael, et al.
Publicado: (2013)

Corrigendum: Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
por: Leutner, Michael, et al.
Publicado: (2021)

Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database
por: Kraus, Christoph, et al.
Publicado: (2023)

Making Sense of: Sensitization in Schizophrenia
por: Weidenauer, Ana, et al.
Publicado: (2016)

Implementing prevention of seasonal affective disorder from patients’ and physicians’ perspectives – a qualitative study
por: Nussbaumer-Streit, Barbara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rre2canufmk2obr4vqsna2ku6l